Continuous Improvement and the Expansion of Quality ... - NCQA

Recommendations

Info

T H E S TAT E o f H E A l T H C A R E Q U A l I T y 2 0 1 1 • H E D I S M E A S U R E S o f C A R E monitoring of patients on persistent medications would reduce the likelihood of hospitalization and ED visits and increase adherence rates. yEAR aCE InHIbItors or arbs CoMMERCIAl MEDICARE MEDICAID HMo PPo HMo PPo HMo 2010 81.6 78.4 90.7 90.8 86.0 2009 80.8 77.6 89.6 89.8 85.9 2008 79.4 76.4 86.7 88.8 84.8 2007 77.2 75.6 84.8 87.8 82.5 2006 74.8 66.3 82.7 83.9 79.9 yEAR antIConvulsants CoMMERCIAl MEDICARE MEDICAID HMo PPo HMo PPo HMo 2010 60.4 57.9 68.2 69.1 67.7 2009 62.0 59.2 69.7 68.5 68.7 2008 61.7 59.0 67.5 70.0 68.7 2007 59.6 56.3 65.1 66.0 65.9 2006 59.4 49.8 63.6 64.9 63.6 yEAR dIgoxIn CoMMERCIAl MEDICARE MEDICAID HMo PPo HMo PPo HMo 2010 84.6 79.1 93.1 92.7 89.7 2009 83.6 77.9 92.0 92.2 88.9 2008 81.9 76.6 90.4 91.1 88.5 2007 79.7 75.7 87.9 90.4 84.9 2006 77.3 64.2 86.2 87.1 83.0 yEAR dIurEtICs CoMMERCIAl MEDICARE MEDICAID HMo PPo HMo PPo HMo 2010 81.0 78.1 90.9 91.2 85.5 2009 80.4 77.2 89.8 90.3 85.4 2008 79.1 76.1 87.1 89.1 84.2 2007 76.8 75.2 84.8 87.6 81.3 2006 74.4 65.7 83.0 84.1 79.1 yEAR CoMbInEd 67 CoMMERCIAl MEDICARE MEDICAID HMo PPo HMo PPo HMo 2010 80.9 77.8 90.2 90.6 83.9 2009 80.3 77.0 89.2 89.7 83.2 2008 78.9 75.8 86.3 88.6 82.6 2007 76.6 74.9 84.3 87.2 80.1 2006 74.3 65.6 82.2 83.6 77.7 C H R o N I C D I S E A S E M A N A G E M E N T
C H R o N I C D I S E A S E M A N A G E M E N T 68 Major depression is considered a serious medical illness; it affects approximately 5 percent– 8 percent of American adults. 1 Depression is the leading cause of disability in the United States. 1 Symptoms include persistent sadness, loss of energy, loss of appetite and inability to concentrate. 2 The Antidepressant Medication Management measure assesses short-term and long-term medication adherence rates for adults newly diagnosed with depression. • According to evidence-based guidelines, medication management reduces the risk of relapse and reoccurrence for patients with depression. Without antidepressant medication, 50 percent–80 percent of patients have major depressive relapses and reoccurrences. 3 • The need for antidepressant medication increases as the severity of depression intensifies. 2 N AT I o N A l C o M M I T T E E f o R Q U A l I T y A S S U R A N C E ANTIDEPRESSANT MEDICATIoN MANAGEMENT the Case for Improvement • Major depression accounts for a variety of indirect economic costs resulting from personal developmental delays and productivity losses. 4 Personal income loss for people with depression reaches an average of $10,400 annually, with a lifetime total cost of $300,000. 5 Individuals with depression take an average of 10 sick days a year. 6 Time missed from work or school due to depression is higher than many anxiety and emotional disorders. • Inefficiencies in diagnosing and applying evidence-based treatments for depression add to loss of productivity and affect mental and physical well-being. 7,8 • The risk of physical and functional impairments because of missed work or school can increase as well-being deteriorates. Responsible, evidence-based medication management may improve the secondary impact of the disease. 9 HEdIs Measure definition The percentage of adults 18 years of age and older who were diagnosed with a new episode of major depression and treated with antidepressant medication, and who remained on an antidepressant medication treatment. Two rates are reported. • Effective Acute Phase Treatment. The percentage of newly diagnosed and treated people who remained on an antidepressant medication for at least 84 days (12 weeks).
Page 1 and 2:
Continuous Improvement and the Expa
Page 3 and 4:
2 This Report and the data containe
Page 5 and 6:
4 N AT I o N A l C o M M I T T E E
Page 7 and 8:
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
top 10 and bottom 10 states “loca
Page 15 and 16:
Page 17 and 18: 16 this measure has shown steady ga
Page 19 and 20: 18 N AT I o N A l C o M M I T T E E
Page 25 and 26: 24 HEDIS MEASURES of CARE about HEd
Page 27 and 28: S A f E T y A N D P o T E N T I A l
Page 37 and 38: W E l l N E S S A N D P R E V E N T
Page 49 and 50: C H R o N I C D I S E A S E M A N A
Page 67: C H R o N I C D I S E A S E M A N A
Page 73 and 74: M E A S U R E S T A R G E T E D A T
Page 119 and 120:
M E A S U R E S T A R G E T E D A T
Page 121 and 122:
C o N S U M E R A N D P A T I E N T
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
128 N AT I o N A l C o M M I T T E
Page 131 and 132:
130 APPENDIx 1: HEDIS EffECTIVENESS
Page 133 and 134:
Page 135 and 136:
134 APPENDIx 2: HEDIS EffECTIVENESS
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
142 APPENDIx 4b: ACCREDITED VS. NoN
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
148 APPENDIx 6A: ACCREDITED VS. NoN
Page 151 and 152:
150 APPENDIx 6b: ACCREDITED VS. NoN
Page 153 and 154:
152 APPENDIx 7A: PUblICly REPoRTING
Page 155 and 156:
Page 157 and 158:
Page 159 and 160:
158 APPENDIx 8: PUblICly REPoRTING
Page 161 and 162:
Page 163 and 164:
Page 165 and 166:
Page 167 and 168:
Page 169 and 170:
Page 171 and 172:
Page 173 and 174:
172 MEASURE N AT I o N A l C o M M
Page 175 and 176:
174 APPENDIx 14b: VARIATIoN IN PlAN
Page 177 and 178:
Page 179 and 180:
Page 181 and 182:
180 APPENDIx 16A: VARIATIoN IN PlAN
Page 183 and 184:
182 APPENDIx 16b: VARIATIoN IN PlAN
Page 185 and 186:
184 REfERENCES N AT I o N A l C o M
Page 187 and 188:
Page 189 and 190:
Page 191 and 192:
Page 193 and 194:
Page 195 and 196:
Page 197 and 198:
Page 200 and 201:
ACkNoWlEDGMENTS Health Plans The 20
show all

Continuous Improvement and the Expansion of Quality ... - NCQA

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?